Advisory Services Network, LLC Denali Therapeutics Inc. Transaction History

Advisory Services Network, LLC

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 09, 2024	BUY	$16.2 - $23.18 $5,005 - $7,162	309 New	309 $6,000
Q4 2022 Feb 13, 2023	BUY	$26.28 - $33.92 $7,884 - $10,176	300 New	300 $8,000
Q3 2021 Nov 05, 2021	SELL	$48.48 - $78.23 $93,178 - $150,358	-1,922 Closed	0 $0
Q2 2021 Aug 12, 2021	SELL	$50.3 - $78.44 $86,365 - $134,681	-1,717 Reduced 47.18%	1,922 $151,000
Q1 2021 May 24, 2021	SELL	$53.8 - $81.53 $111,419 - $168,848	-2,071 Reduced 36.27%	3,639 $208,000
Q4 2020 Feb 09, 2021	BUY	$36.89 - $93.56 $3,356 - $8,513	91 Added 1.62%	5,710 $478,000
Q3 2020 Nov 16, 2020	BUY	$23.13 - $38.84 $129,967 - $218,241	5,619 New	5,619 $201,000
Q2 2020 Aug 10, 2020	SELL	$16.01 - $28.82 $83,988 - $151,189	-5,246 Closed	0 $0
Q1 2020 May 15, 2020	BUY	$14.2 - $27.98 $74,493 - $146,783	5,246 New	5,246 $92,000

226

119M

60.6K

48.4K

Ticker DNLI
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 134,174,000
Market Cap $3.13B
Description
Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutic candidates for neurodegenerative diseases in the United States. It offers leucine-rich repeat kinase 2 (LRRK2) inhibitor product candidate, including BIIB122/DNL151, a small molecule inhibitor, which is in phase I and phase Ib clinical trials for the treatm...

Get notified when there are updates to the investment portfolio of Advisory Services Network, LLC, based on Form 13F filings with the SEC.

Stay updated on Advisory Services Network, LLC with notifications on news.